Par Recalls More Treprostinil Due to Silicone in the Product
An additional seven lots of Treprostinil are affected on top of last month’s recall of one lot.
Par Pharmaceutical, a part of Endo International, is expanding its recall to include seven additional lots of Treprostinil Injection 20mg/20mL. The product is being recalled because of the possibility of silicone particulates in the product, the company said in a news release.
Treprostinil Injection is a prostacyclin vasodilator used to treat patients with pulmonary arterial hypertension and for patients who require transition from epoprostenol. The presence of silicone can result in local irritation or swelling at the injection site. If the silicone particulates reach the blood vessels it can travel to various organs and block blood vessels in the heart, lungs or brain.
Treprostinil Injection is distributed in multidose vials as sterile solutions in water for injection with individually packaged in cartons with the NDC #42023-206-01. The lots were distributed nationwide to wholesalers and hospitals from June 16, 2022, through Aug. 7, 2023. The lots affected by this recall can be found here.
Related: Silicone Particles in Product Leads to Recall of Treprostinil
Last month, Par had recalled one lot of Treprostinil Injection for the same reason.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
